Esketamine nasal spray added to current antidepressants for major depression
Tests esketamine nasal spray added to ongoing antidepressants in adults with depression.
Plain-language title generated from the registry record
Registry title: Positioning of Esketamine Treatment in the Real-world Management of Depression
Key facts
- Where
- St Leonards, AustraliaSee the site
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT06103760, who can take part
Where in Australia
- Royal North Shore HospitalSt Leonards, AustraliaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Royal North Shore Hospital
- Trial code
- NCT06103760
- Record updated
- 12 August 2026
- Original description
The goal of this naturalistic, open label, single arm intervention study is to investigate the effects of Esketamine in treating depression.The main aims to answer are:Read full original descriptionShow less
Positioning of Esketamine Treatment in the Real-world Management of Depression
The goal of this naturalistic, open label, single arm intervention study is to investigate the effects of Esketamine in treating depression.The main aims to answer are:
* to investigate whether Esketamine is effective when added to ongoing antidepressant treatment * to identify patient characteristics that will determine a therapeutic response to Esketamine in real-world practice
Participants will:
* attend the clinic for supervised self-administration of intranasal Esketamine treatment * be observed for 2 hours following Esketamine administration including blood pressure monitoring * be asked to complete a battery of questionnaires * be reimbursed for travel expenses
Inclusion: Adults aged 18-65 years old; Diagnosis of Major Depressive Disorder (MDD); Currently depressed; Had an inadequate response to 2 or more courses of antidepressants (of adequate dose and duration); Be maintained on their current antidepressant medication or psychological therapy at the time of enmrolment; Able to understand and provide informed consent.
Exclusion: Concurrent diagnoses:; Participants with other 'Diagnostic and Statistical Manual of Mental Disorders' (DSM-5) e.g., current substance misuse disorder, bipolar disorder, schizophrenia; Participants who are unable to understand the study and therefore unable to provide informed consent; Current medications:; Participants taking a total daily dose of benzodiazepines greater than the equivalent of 6mg/day of lorazepam; Participants on complementary and alternative medicine therapies i.e., St John's wort, Chinese medicines, and various herbal and homeopathic treatments; Stimulants; Participants taking stimulants such as methylphenidate, amphetamine, and dextroamphetamine for a diagnosis such as ADHD can still have Esketamine provided they do not continue taking stimulants concurrently for the duration of the study; Concurrent use is excluded due to the synergistic effect with Esketamine that can cause increased blood pressure; Medical history:; Participants with current or past history of seizures (uncomplicated childhood febrile seizures with no sequelae are not exclusionary); Participants with a history of uncontrolled hypertension; Participants with uncontrolled diabetes mellitus; Participants with aneurysmal vascular disease including thoracic and abdominal aorta, intracranial and peripheral arterial vessels, or arteriovenous malformation, intracerebral haemorrhage; Participants with untreated glaucoma, current penetrating or perforating eye injury, brain injury, hypertensive encephalopathy, intrathecal therapy with ventricular shunts, or any other condition associated with increased intracranial pressure or increased intraocular pressure or planned eye surgery; Participants who are currently receiving electroconvulsive therapy (ECT) or have received ECT in the past month; Substance Misuse History:; Participants who have ever had a substance misuse disorder involving any of the following over their lifetime: ketamine, phencyclidine (PCP), lysergic acid diethylamide (LSD), or 3,4-methylenedioxy-methamphetamine (MDMA), or other hallucinogen use history; Participants with hypersensitivity to Esketamine, Ketamine, or any of the excipients; Pregnancy:; Participants who are pregnant and/or breastfeeding; Participants who are not willing to avoid pregnancy for themselves or their partners during the study by using effective birth control methods.